Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.96 (market cap $176.64M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 12.9× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| RDTE | SLS | |
|---|---|---|
Market Cap | $176.64M | $2.28B |
Volume | 116,818 | 3,128,960 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $15.46 |
52-Week Low | $25.96 | $1.39 |
Typical Hold Time | 53 Days | — |
Enterprise Value | — | $2.15B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
